A clinical investigation into PTC299, an oral dihydroorotate dehydrogenase (DHODH) inhibitor, as a potential treatment for COVID-19* is discussed in this PTC-sponsored webinar from 2020
Webinar: Scientific updates on investigation of small molecules in patients with COVID-19
Register here to access the content on the site
MED-ALL-CORP-2200029 | December 2022
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our Privacy Statement and our Terms and Conditions do not apply.
We encourage you to read the Privacy Policy and the Terms and Conditions of every website you visit. PTC Therapeutics does not endorse and/or influence the content found on websites not owned/operated by PTC Therapeutics.
MED-ALL-CORP-2200029 | December 2022
COMING SOON
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.